Sarcoma News

On Nov. 26, the FDA announced the accelerated approval of larotrectinib as the first small molecule inhibitor for use in a “cancer-agnostic” manner, in pediatric and adult human cancers that harbor neurotrophic receptor tyrosine kinase gene fusions.

The NIH awarded a 5-year, $693,000 grant to The Feinstein Institute for Medical Research to develop and test a digital health platform to help young female cancer survivors evaluate their options for having children and plan for the future.

Rates of therapy-related myelodysplastic syndrome and acute myeloid leukemia have risen significantly in the modern era following chemotherapy for nearly all solid tumor cancer types, according to results of a population-based cohort study published in JAMA Oncology.

Patients with progressive, refractory or symptomatic desmoid tumors derived a significant PFS benefit from sorafenib, according to results of a double-blind, placebo-controlled randomized phase 3 study published in The New England Journal of Medicine.

The FDA today issued new guidance to help drug developers select endpoints for marketing applications with the goal of advancing the efficient development of cancer drugs and biologics.

The FDA granted accelerated approval to larotrectinib for the treatment of adults and children with solid tumors that have a neurotrophic receptor tyrosine kinase gene fusion without a known acquired resistance mutation.

NEW YORK — The treatment landscape in sarcoma is evolving rapidly as the research community recognizes the importance of matching therapies to specific molecularly defined histologies, according to a presenter at Chemotherapy Foundation Symposium.

The FDA approved levoleucovorin, a folate analog, for injection for three indications.

MUNICH — The use of complementary and alternative medicine for sarcoma, gastrointestinal stromal tumors or desmoid tumors appeared more common among women and older patients, according to study results presented at European Society for Medical Oncology Congress.

Inaccurate coding may lead to underreporting of sarcoma cases in national databases, according to a research letter published in JAMA Oncology.